Accessibility Tools

Medication Legend

℞: Medications that treat viral infections and tumors are marked with the "℞" symbol.
+: Medications that contain proteins for weight gain are marked with the "+" symbol.
++: Regenerative medications for neurogenesis are marked with the "++" symbol.

Xiankun (Kevin) Zeng, Ph.D., a molecular biologist and principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), is the recipient of the 2021-2022 Research and Development Award presented by AMSUS, the Society of Federal Health Professionals.

Zeng was honored during the AMSUS virtual annual meeting on Feb 24.

In the early days of the COVID-19 pandemic, Zeng was the first scientist to quickly develop and validate highly reliable and sensitive molecular pathology assays to detect SARS-CoV-2 infection in tissue samples. These assays proved to be a cornerstone of SARS-CoV-2 research, enabling scientists to perform natural history studies that mapped the disease course of this novel virus.

Importantly, Zeng’s research also supported USAMRIID’s ability to rapidly develop several COVID-19 animal models that successfully recapitulated human disease in mice, hamsters, and nonhuman primates. These models are essential for preclinical evaluation of vaccines, therapies, and diagnostic tools—an important step in the pathway to licensure by the U.S. Food and Drug Administration.

Xiankun (Kevin) Zeng, Ph.D., a molecular biologist and principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), is the recipient of the 2021-2022 Research and Development Award presented by AMSUS, the Society of Federal Health Professionals. Photo: USAMRIID Courtesy Photo

His research paper reporting these assays appeared in JCI Insight, a journal published by the American Society for Clinical Investigation, in 2020. It was the first of many SARS-CoV-2 publications from USAMRIID. Since then, Zeng has continued to collaborate with a dozen research teams worldwide, helping them to develop and validate their own SARS-CoV-2 assays.

“I am very honored and humbled to be receiving this award,” said Zeng, who has served with USAMRIID’s Pathology Division since May 2015. He previously worked as a research scientist at the Howard Hughes Medical Institute (Janelia Research Campus) after completing his postdoctoral research training at the National Cancer Institute, National Institutes of Health. He earned his Ph.D. in molecular genetics from Southeast University, China, in 2007.

In addition to his contributions to SARS-CoV-2 research, Zeng is a leading expert on persistent infection of other highly pathogenic viruses, such as Ebola virus, Marburg virus, Nipah virus, and Lassa virus. He has over 75 scientific publications to his credit, including 13 papers on SARS-CoV-2, and his research has been published in Nature, Nature Microbiology, Science Translational Medicine, and Cell Host & Microbe.

SEE ALSO:

Content Original Link:

https://globalbiodefense.com/2022/02/25/usamriid-scientist-wins-amsus-research-and-development/

Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.

VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.